S. Paul Oh, PhD, is a professor in the Division of Neurobiology at Barrow Neurological Institute.
Dr. Oh’s expertise includes vascular and cell biology. He is a member of the American Heart Association and the North American Vascular Biology Organization.
Dr. Oh earned his doctorate degree in cell and developmental biology from Harvard University. He completed postdoctoral fellowships in the Department of Medicine and the Department of Cell Biology at Harvard Medical School. Before coming to Barrow, Dr. Oh served as a professor in the Department of Physiology and Functional Genomics at the University of Florida, where he worked for 20 years.
Dr. Oh’s research interests include identifying cellular mechanisms responsible for cerebrovascular disorders and assessing novel therapies to treat these disorders.
- Postdoctoral Fellow, Harvard Medical School, Department of Medicine, 1994-1997
- Research Fellow, Massachusetts General Hospital, Cardiovascular Research Center, 1994-1997
- Postdoctoral Fellow, Harvard Medical School, Department of Cell Biology, 1993-1994
- PhD, Harvard University, Cell and Developmental Biology, 1993
- Research Assistant, Southwestern Medical School, Department of Ophthalmology, 1985-1987
- BS, Korea University, Chemistry, 1985
- American Heart Association
- North American Vascular Biology Organization
- PhD Thesis Mentor’s Award, University of Florida, College of Medicine, 2012
- Outstanding Poster Award, NIH Trans-Institute Angiogenesis Research Program Workshop: Inflammation and Perivascular Environment, 2007
- Exemplary Teacher, University of Florida, College of Medicine, 2005, 2008
- Best Poster Presentation, Faculty Research Day, University of Florida, College of Medicine, 2002
- Larry Gentry Memorial Award for Most Outstanding Poster, Third International Conference for TGF-ß, National Institutes of Health, 1999
- Individual National Research Service Award, National Institute of Child Health and Human Development, 1995-1997
- Outstanding Presentation Award, East Coast Connective Tissue Society, 1993
- Predoctoral Training Grant, National Institutes of Health, 1987-1990
- Kim YH, Kim MJ, Choe SW, Sprecher D, Lee YJ, S PO. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. J Thromb Haemost. 2017;15(6):1095-1102.
- Moon EH, Kim YS, Seo J, Lee S, Lee YJ, Oh SP. Essential role for TMEM100 in vascular integrity but limited contributions to the pathogenesis of hereditary haemorrhagic telangiectasia. Cardiovasc Res. 2015;105(3):353-360.
- Han C, Choe SW, Kim YH, Acharya AP, Keselowsky BG, Sorg BS, Lee YJ, Oh SP. VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis. 2014;17(4):823-830.
- Garrido-Martin EM, Nguyen HL, Cunningham TA, Choe SW, Jiang Z, Arthur HM, Lee YJ, Oh SP. Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models–brief report. Arterioscler Thromb Vasc Biol. 2014;34(10):2232-2236.
- Park SO, Wankhede M, Lee YJ, Choi EJ, Fliess N, Choe SW, Oh SH, Walter G, Raizada MK, Sorg BS, Oh SP. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest. 2009;119(11):3487-3496.
- Park SO, Lee YJ, Seki T, Hong KH, Fliess N, Jiang Z, Park A, Wu X, Kaartinen V, Roman BL, Oh SP. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood. 2008;111(2):633-642.
- Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H, Li E, Raizada MK, Bloch KD, Oh SP. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation. 2008;118(7):722-730.
- Seki T, Hong KH, Yun J, Kim SJ, Oh SP. Isolation of a regulatory region of activin receptor-like kinase 1 gene sufficient for arterial endothelium-specific expression. Circ Res. 2004;94(8):e72-77.
- Seki T, Yun J, Oh SP. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res. 2003;93(7):682-689.
- Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A. 2000;97(6):2626-2631.